UNSPSC 51351503: Dimethisterone

This classification denotes a therapeutic progestin with the molecular formula C23H32O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4MZ02M175, chemically known as 17-alpha-pregn-4-en-20-yn-3-one, 6-alpha,21-dimethyl-17-hydroxy- but generally known as dimethisterone, which bears US NIH Compound Identifier 6607. European Medicines Agency schedules Dimethisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07173MIG.

UNSPSC 51351503 Dimethisterone is a Commodity code covering synthetic progestin pharmaceuticals, but the recent state and local opportunities tagged under it reflect broader generic multi-source pharmaceutical and over-the-counter product sourcing rather than dimethisterone specifically. State and local health systems, correctional facilities, and agency medical programs procure generic pharmaceuticals through cooperative purchasing vehicles, typically requiring submission of National Drug Codes, pricing across authorized wholesaler networks, compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and demonstration of electronic data interchange capability. Issuing bodies include state health departments and multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves participating state and local government facilities across multiple states including Oregon and actively solicits pharmaceutical manufacturers and suppliers for multi-award contracts.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (solicitation S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), submit detailed product information in CSV format, and carry insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. Evaluation weighs price competitiveness at 75 percent, fixed pricing at 10 percent, EDI capability at 5 percent, administrative fee compliance at 5 percent, and data format compliance at 5 percent. Contract terms run two years for new responders with optional MMCAP extensions, or through June 30, 2028 for incumbents, with a 3 percent administrative fee on all purchases and performance penalties ranging from $200 to $1,500 per violation.